Laurenz De Cock

Laurenz De Cock

Auto-generated profile, based on publicly available information

Laurenz De Cock

Cancer Research Institute Ghent (CRIG), Ghent, Belgium. 2

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2024 in Cell Reports Medicine
Verified
Journal Article
Open access
JIJoline Ingels
Joline Ingels
LCLaurenz De Cock
Laurenz De Cock
DSDieter Stevens
Dieter Stevens
RMRupert L. Mayer
Rupert L. Mayer
FTFabien Théry
Fabien Théry
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
Non-small cell lung cancer (NSCLC) is known for high relapse rates despite resection in early stages. Here, we present the results of a phase I clinical trial in which a dendritic cell (DC) vaccine targeting patient-individual neoantigens is evaluated in patients with resected NSCLC. Vaccine manufacturing is feasible in six of 10 enrolled patients. Toxicity is limited to grade 1-2 adverse events. Systemic T cell responses are observed in five out of six vaccinated patients, with T cell responses remaining detectable up to 19 months post vaccination. Single-cell analysis indicates that the responsive T cell population is polyclonal and exhibits the near-entire spectrum of T cell differentiation states, including a naive-like state, but excluding exhausted cell states. Three of six vaccinated patients experience disease recurrence during the follow-up period of 2 years. Collectively, these data support the feasibility, safety, and immunogenicity of this treatment in resected NSCLC.

1 February 2022 in Cytotherapy
Verified
Journal Article
Open access
JIJoline Ingels
Joline Ingels
LCLaurenz De Cock
Laurenz De Cock
RMRupert Mayer
Rupert Mayer
PDPam Devreker
Pam Devreker
KWKarin Weening
Karin Weening
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
Messenger RNA (mRNA) has become a promising tool in therapeutic cancer vaccine strategies. Owing to its flexible design and rapid production, mRNA is an attractive antigen delivery format for cancer vaccines targeting mutated peptides expressed in a tumor-the so-called neoantigens. These neoantigens are rarely shared between patients, and inclusion of these antigens in a vaccine requires the production of individual batches of patient-tailored mRNA. The authors have developed MIDRIXNEO, a personalized mRNA-loaded dendritic cell vaccine targeting tumor neoantigens, which is currently being evaluated in a phase 1 clinical study in lung cancer patients. To facilitate this study, the authors set up a Good Manufacturing Practice (GMP)-compliant production process for the manufacture of small batches of personalized neoantigen-encoding mRNA. In this article, the authors describe the complete mRNA production process and the extensive quality assessment to which the mRNA is subjected. Validation runs have shown that the process delivers mRNA of reproducible, high quality. This process is now successfully applied for the production of neoantigen-encoding mRNA for the clinical evaluation of MIDRIXNEO. To the authors' knowledge, this is the first time that a GMP-based production process of patient-tailored neoantigen mRNA has been described.

14 June 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
SMStijn De Munter
Stijn De Munter
JBJuliane L. Buhl
Juliane L. Buhl
LCLaurenz De Cock
Laurenz De Cock
APAlexander Van Parys
Alexander Van Parys
WDWillem Daneels
Willem Daneels
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
CD70 is an attractive target for chimeric antigen receptor (CAR) T-cell therapy for the treatment of both solid and liquid malignancies. However, the functionality of CD70-specific CAR T cells is modest. We optimized a CD70-specific VHH-based CAR (nanoCAR). We evaluated the nanoCARs in clinically relevant models in vitro, using co-cultures of CD70-specific nanoCAR T cells with malignant rhabdoid tumor organoids, and in vivo, using a diffuse large B-cell lymphoma patient-derived xenograft (PDX) model. Although the nanoCAR T cells were highly efficient in organoid co-cultures, they showed only modest efficacy in the PDX model. We determined that fratricide was not causing this loss in efficacy but rather CD70 interaction in cis with the nanoCAR-induced exhaustion. Knocking out CD70 in nanoCAR T cells using CRISPR/Cas9 resulted in dramatically enhanced functionality in the diffuse large B-cell lymphoma PDX model. Through single-cell transcriptomics, we obtained evidence that CD70 knockout CD70-specific nanoCAR T cells were protected from antigen-induced exhaustion. In addition, we demonstrated that wild-type CD70-specific nanoCAR T cells already exhibited signs of exhaustion shortly after production. Their gene signature strongly overlapped with gene signatures of exhausted CAR T cells. Conversely, the gene signature of knockout CD70-specific nanoCAR T cells overlapped with the gene signature of CAR T-cell infusion products leading to complete responses in chronic lymphatic leukemia patients. Our data show that CARs targeting endogenous T-cell antigens negatively affect CAR T-cell functionality by inducing an exhausted state, which can be overcome by knocking out the specific target.

20 March 2023 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
LBLore Billiet
Lore Billiet
LCLaurenz De Cock
Laurenz De Cock
GSGuillem Sanchez Sanchez
Guillem Sanchez Sanchez
RMRupert Mayer
Rupert Mayer
GGGlenn Goetgeluk
Glenn Goetgeluk
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
In the human thymus, a CD10+ PD-1+ TCRαβ+ differentiation pathway diverges from the conventional single positive T cell lineages at the early double-positive stage. Here, we identify the progeny of this unconventional lineage in antigen-inexperienced blood. These unconventional T cells (UTCs) in thymus and blood share a transcriptomic profile, characterized by hallmark transcription factors (i.e., ZNF683 and IKZF2), and a polyclonal TCR repertoire with autoreactive features, exhibiting a bias toward early TCRα chain rearrangements. Single-cell RNA sequencing confirms a common developmental trajectory between the thymic and blood UTCs and clearly delineates this unconventional lineage in blood. Besides MME+ recent thymic emigrants, effector-like clusters are identified in this heterogeneous lineage. Expression of Helios and KIR and a decreased CD8β expression are characteristics of this lineage. This UTC lineage could be identified in adult blood and intestinal tissues. In summary, our data provide a comprehensive characterization of the polyclonal unconventional lineage in antigen-inexperienced blood and identify the adult progeny.

22 January 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
SMStijn De Munter
Stijn De Munter
JBJuliane Buhl
Juliane Buhl
LCLaurenz De Cock
Laurenz De Cock
APAlexander Van Parys
Alexander Van Parys
WDWillem Daneels
Willem Daneels
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
CD70 is an attractive target for chimeric antigen receptor (CAR) T cell therapy as treatment for both solid and liquid malignancies. However, functionality of CD70-specific CARs is only modest. Here, we optimized a CD70-specific VHH based CAR (nanoCAR). We evaluated the nanoCARs in clinically relevant models in vitro , using co-cultures of CD70-specific nanoCAR T cells with malignant rhabdoid tumor organoids, and in vivo by using a diffuse large B cell lymphoma (DLBCL) patient-derived xenograft (PDX) model. Whereas the nanoCAR T cells were highly efficient in organoid co-cultures, they showed only modest efficacy in the PDX model. Knocking out CD70 expression by the nanoCAR T cells resulted in dramatically enhanced functionality in the PDX model, suggesting that endogenous CD70 interaction with the nanoCAR induces exhaustion. Through single-cell transcriptomics, we obtained evidence that CD70KO CD70-specific nanoCAR T cells are protected from antigen induced exhaustion. Our data shows that CARs targeted to endogenous T cell antigens, negatively affect CAR T cell functionality by inducing an exhausted state which can be overcome by knocking out the specific target, in this case CD70.

17 June 2026
Verified
Other
Open access
SMStijn De Munter
Stijn De Munter
JBJuliane L. Buhl
Juliane L. Buhl
LCLaurenz De Cock
Laurenz De Cock
APAlexander Van Parys
Alexander Van Parys
WDWillem Daneels
Willem Daneels
Bart VandekerckhoveBart Vandekerckhove
Bart Vandekerckhove
Differential gene expression reveals distinct differences between the clusters.